Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Phase

Condition

Vascular Diseases

Circulation Disorders

Williams Syndrome

Treatment

Minocycline Hydrochloride

Placebo

Clinical Study ID

NCT06246396

IRB202301939

2R01HL132448-05A1

5R01HL132448-04

Ages 18-85
All Genders

Study Summary

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are:

To what extent does minocycline lower blood pressure and are these effects different across races?
Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these?

Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Age ≥18 years
Self-identify as White or African American
Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatorysystolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥30 days prior) antihypertensive regimen of 3 or more drugs,including an adequately dosed thiazide or thiazide-like diuretic (hydrochlorothiazide ≥25 mg/day or equivalent)
The participant agrees to have all study procedures performed

Exclusion

Exclusion Criteria:

Known hypersensitivity or contraindication to minocycline or other tetracyclines
Recent (≤3 months prior), ongoing, or expected use of oral antibiotics
Estimated glomerular filtration rate (eGFR) of <45mL/min/1.73m2, using the MDRDequation
Known secondary hypertension
History of antihypertensive crisis, defined as any in-patient hospitalizations forantihypertensive crisis/emergency within the past year
History of orthostatic hypotension, defined as two or more episode(s) of orthostatichypotension (reduction of SBP of >20 mm Hg or DBP of >10 mm Hg within 3 minutes ofstanding) in the past year
History of myocardial infarction, unstable angina, syncope, or cerebrovascularaccident in prior 6 months
Evidence of alcoholism or drug abuse
Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS)
Ongoing or expected use of significant BP-interfering medications (excepting oralcontraceptives)
Current pregnancy or anticipated pregnancy during the study.

Study Design

Minocycline Hydrochloride

January 08, 2025

July 31, 2028

Study Description

One hundred twenty patients (targeting 60 White patients and 60 Black or African American [AA] patients) with treatment-resistant hypertension will be enrolled. A total of 34 patients (17 from each treatment arm, with similar race distribution), who are participants in the main study, will also be enrolled in a substudy that includes neuroimaging. The study will last 3 months, and will include 3 visit time points (screening, randomization visit, 3-month follow-up visit).

Participants will be randomly assigned, in a 1:1 allocation, to minocycline 100 mg twice per day, or matching placebo, each provided by the study, and investigators will be blinded to treatment assignment.

At the baseline and 3-month follow-up visit, subjects will undergo:

A comprehensive medical history and examination, including assessment of antihypertensive treatment history
A series of behavioral activity questionnaires
Blood tests (plasma renin activity, aldosterone, catecholamines, serum creatinine, lipid panel, hemoglobin a1c, as well as various biomarkers of immune and inflammatory activity, and gut leakiness markers)
Urine/saliva tests for antihypertensive adherence
Gut microbiota profiling via whole metagenomic sequencing of stool samples
Blood pressure (BP) measurement, including unattended office BP and 24-hour ambulatory BP

Subjects enrolled in the neuroimaging substudy will also have PET/MR imaging performed at each visit. Neuroimaging activities will take place at Emory University in Atlanta, GA.

At the final visit (3-month follow-up), participants will also have blood tests to measure study drug concentration, as a measure of adherence to the assigned treatment.

Connect with a study center

UF Health Cardiology - Heart & Vascular Hospital
Gainesville, Florida 32610
United States
Active - Recruiting
UF Health Cardiovascular Clinic
Gainesville, Florida 32610
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.